These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10394964)

  • 21. Paclitaxel premedication regimens.
    Boehm DK; Maksymiuk AW
    J Natl Cancer Inst; 1996 Apr; 88(7):463-5. PubMed ID: 8618242
    [No Abstract]   [Full Text] [Related]  

  • 22. Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel.
    Gennari A; Salvadori B; Tognoni A; Conte PF
    Ann Oncol; 1996 Nov; 7(9):978-9. PubMed ID: 9006754
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions.
    Jao ME; Indorf AL; Segal EM; Miske A; Eaton KD; Marsolini T; Ghuman S
    J Oncol Pharm Pract; 2024 Jan; 30(1):105-111. PubMed ID: 37021579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy.
    Xiao D; Yang Z; Shi Y; Yang W; Zhang Y
    Expert Rev Clin Pharmacol; 2024; 17(5-6):525-532. PubMed ID: 38652518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.
    Zidan J; Hussein O; Abzah A; Tamam S; Farraj Z; Friedman E
    Med Oncol; 2008; 25(3):274-8. PubMed ID: 18363113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histamine-2 (H
    Foreman E; Polwart C; Walker A; Chambers P
    Br J Clin Pharmacol; 2022 Sep; 88(9):4191-4198. PubMed ID: 35470452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.
    Chen FC; Wang LH; Zheng XY; Zhang XM; Zhang J; Li LJ
    Oncotarget; 2017 Mar; 8(12):19236-19243. PubMed ID: 27911278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
    Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
    Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial.
    Yanaranop M; Chaithongwongwatthana S
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):289-99. PubMed ID: 27098551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
    Köppler H; Heymanns J; Weide R
    Onkologie; 2001 Jun; 24(3):283-5. PubMed ID: 11455223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
    Berger MJ; Dunlea LJ; Rettig AE; Lustberg MB; Phillips GS; Shapiro CL
    Support Care Cancer; 2012 Sep; 20(9):1991-7. PubMed ID: 22089428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
    J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful re-treatment with taxol after major hypersensitivity reactions.
    Peereboom DM; Donehower RC; Eisenhauer EA; McGuire WP; Onetto N; Hubbard JL; Piccart M; Gianni L; Rowinsky EK
    J Clin Oncol; 1993 May; 11(5):885-90. PubMed ID: 8098057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions.
    Durham CG; Thotakura D; Sager L; Foster J; Herrington JD
    J Oncol Pharm Pract; 2019 Sep; 25(6):1396-1401. PubMed ID: 30419768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
    Vogt HG; Kolotas C; Martin T; Schneider LV; Goes-Schmieder R; Mitrou PS; Diergarten K; Kober B; Zamboglou N
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):120-3. PubMed ID: 9007138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma].
    Komatsubara K; Miyoshi K; Kogure Y; Matsuhisa T; Eguchi H
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):107-10. PubMed ID: 20087041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
    Slichenmyer WJ; Donehower RC; Chen TL; Bowling MK; McGuire WP; Rowinsky EK
    Cancer Chemother Pharmacol; 1995; 36(3):227-32. PubMed ID: 7781143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer].
    Kuroi K; Tanaka C; Bando H; Saji S; Hayashi K; Toi M
    Gan To Kagaku Ryoho; 2002 Jan; 29(1):55-60. PubMed ID: 11816478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergency. Chemotherapy-induced hypersensitivity reaction.
    Myers JS; Kearney K
    Am J Nurs; 2000 Apr; 100(4):53-4. PubMed ID: 10776352
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.